CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro

Clinical Immunology

Volumn 108, Issue 3, 2003, Pages 234-240

  Salkowitz, Janelle R ^a   Bruse, Shannon E ^a   Meyerson, Howard ^b   Valdez, Hernan ^b   Mosier, Donald E ^c   Harding, Clifford V ^d   Zimmerman, Peter A ^a   Lederman, Michael M ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL STIMULATION; DISEASE COURSE; DNA POLYMORPHISM; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DENSITY; REGULATORY MECHANISM; VIROGENESIS;

EID: 0141565366     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00147-5     Document Type: Article

References (33)

1. Zhu T., Mo H., Wang N., Nam D.S., Cao Y., Koup R.A., Ho D.D. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 261:1993;1179.
2. Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Goedert, J.J., Buchbinder, S.P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, Kaslow, D., Saah, A., Rinaldo, C., Detels, R., Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene, Science 273; (1996) 1856.
3. Huang, Y., Paxton, W.A., Wolinsky, S.M., Neumann, A.U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D., Dragon, E., Landau, N., Phair, J., Ho, D.D., Koup, R., The role of a mutant CCR5 allele in HIV-1 transmission and disease progression, Nat. Med. 2 (1996).
4. O'Brien T.R., Winkler C., Dean M., Nelson J.A., Carrington M., Michael N.L., White G.C. 2nd. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet. 349:1997;1219. [letter] [see comments].
5. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722. [see comments].
6. Smith M.W., Dean M., Carrington M., Huttley G.A., O'Brien S.J. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet. 350:1997;741. discussion 742 [letter; comment].
7. Wang B., Palasanthiran P., Zeigler J., Cunningham A., Saksena N.K. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet. 350:1997;742. [letter; comment].
8. Zimmerman P.A., Buckler-White A., Alkhatib G., Spalding T., Kubofcik J., Combadiere C., Weissman D., Cohen O., Rubbert A., Lam G., Vaccarezza M., Kennedy P.E., Kumaraswami V., Giorgi J.V., Detels R., Hunter J., Chopek M., Berger E.A., Fauci A.S., Nutman T.B., Murphy P.M. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5 studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk . Mol. Med. 3:1997;23.
9. Valdez H., Purvis S.F., Lederman M.M., Fillingame M., Zimmerman P.A. Association of the CCR5 delta 32 mutation with improved response to antiretroviral therapy. J. Am. Med. Assoc. 282:1999;734.
10. Tang J., Shelton B., Makhatadze N.J., Zhang Y., Schaen M., Louie L.G., Goedert J.J., Seaberg E.C., Margolick J.B., Mellors J., Kaslow R.A. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J. Virol. 76:2002;662.
11. McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 352:1998;866.
12. Knudsen T.B., Kristiansen T.B., Katzenstein T.L., Eugen-Olsen J. Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression. J. Med. Virol. 65:2001;441.
13. Clegg A.O., Ashton L.J., Biti R.A., Badhwar P., Williamson P., Kaldor J.M., Stewart G.J. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. AIDS. 14:2000;103.
14. An P., Martin M.P., Nelson G.W., Carrington M., Smith M.W., Gong K., Vlahov D., O'Brien S.J., Winkler C.A. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS. 14:2000;2117.
15. Martin M.P., Dean M., Smith M.W., Winkler C., Gerrard B., Michael N.L., Lee B., Doms R.W., Margolick J., Buchbinder S., Goedert J.J., O'Brien T.R., Hilgartner M.W., Vlahov D., O'Brien S.J., Carrington M. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 282:1998;1907. [In Process Citation].
16. Ometto L., Bertorelle R., Mainardi M., Zanchetta M., Tognazzo S., Rampon O., Ruga E., Chieco-Bianchi L., De Rossi A. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J. Infect. Dis. 183:2001;814.
17. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167.
18. Salkowitz J.R., Purvis S.F., Meyerson H., Zimmerman P., O'Brien T.R., Aledort L., Eyster M.E., Hilgartner M., Kessler C., Konkle B.A., White G.C. 2nd, Goedert J.J., Lederman M.M. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin. Immunol. 98:2001;200.
19. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., et al. Contrasting genetic influence of CCR2 and CCR5 variants in HIV-1 infection and disease progression. Science. 277:1991;959.
20. Kawamura, T., Gulden, F.O., Sugaya, M., McNamara, D.T., Borris, D.L., Lederman, M.M., Orenstein, J.M., Zimmerman, P.A., Blauvelt, A., R5 HIV productively infects Langerhans cells and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci., USA (2003), in press.
21. Division of AIDS, NIAID, DAIDS Virology Manual for HIV Laboratories, Vol. NIH-97-3828. DHHS (Ed.), NIH, Washinton, DC, 1997, p. 46.
22. Iyer S.B., Hultin L.E., Zawadzki J.A., Davis K.A., Giorgi J.V. Quantitation of CD38 expression using QuantiBRITE beads. Cytometry. 33:1998;206.
23. Ioannidis J.P., Rosenberg P.S., Goedert J.J., Ashton L.J., Benfield T.L., Buchbinder S.P., Coutinho R.A., Eugen-Olsen J., Gallart T., Katzenstein T.L., Kostrikis L.G., Kuipers H., Louie L.G., Mallal S.A., Margolick J.B., Martinez O.P., Meyer L., Michael N.L., Operskalski E., Pantaleo G., Rizzardi G.P., Schuitemaker H., Sheppard H.W., Stewart G.J., Theodorou I.D., Ullum H., Vicenzi E., Vlahov D., Wilkinson D., Workman C., Zagury J.F., O'Brien T.R. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression an international meta-analysis of individual-patient data . Ann. Intern. Med. 135:2001;782.
24. Kostrikis L.G., Huang Y., Moore J.P., Wolinsky S.M., Zhang L., Guo Y., Deutsch L., Phair J., Neumann A.U., Ho D.D. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4:1998;350.
25. Michael N.L., Louis L.G., Rohrbaugh A.L., Schultz K.A., Dayhoff D.E., Wang C.E., Sheppard H.W. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat. Med. 10:1997;1160.
26. Gonzalez E., Bamshad M., Sato N., Mummidi S., Dhanda R., Catano G., Cabrera S., McBride M., Cao X.H., Merrill G., O'Connell P., Bowden D.W., Freedman B.I., Anderson S.A., Walter E.A., Evans J.S., Stephan K.T., Clark R.A., Tyagi S., Ahuja S.S., Dolan M.J., Ahuja S.K. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA. 96:1999;12004.
27. Mulherin S.A., O'Brien T.R., Ioannidis J.P., Goedert J.J., Buchbinder S.P., Coutinho R.A., Jamieson B.D., Meyer L., Michael N.L., Pantaleo G., Rizzardi G.P., Schuitemaker H., Sheppard H.W., Theodorou I.D., Vlahov D., Rosenberg P.S. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression the protection varies with duration of infection . AIDS. 17:2003;377.
28. Mangano A., Gonzalez E., Dhanda R., Catano G., Bamshad M., Bock A., Duggirala R., Williams K., Mummidi S., Clark R.A., Ahuja S.S., Dolan M.J., Bologna R., Sen L., Ahuja S.K. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J. Infect. Dis. 183:2001;1574.
29. Akhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC-CKR-5 a RANTES, MIP-1a, MIP-1b receptor as a fusion co-factor for macrophage-tropic HIV-1 . Science. 272:1996;1955.
30. + T cells. Science. 270:1995;1811.
31. Paxton W.A., Liu R., Kang S., Wu L., Gingeras T.R., Landau N.R., Mackay C.R., Koup R.A. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals association with low expression of CCR5 and high production of beta-chemokines . Virology. 244:1998;66.
32. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., O'Brien S.J., Burny A., Gallo R.C. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 95:1998;3857.
33. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA. 94:1997;1925. [see comments].